Bionano Genomics Inc (BNGO) — Financial Flexibility Index
Bionano Genomics Inc (BNGO) has a Financial Flexibility Index of -0.29x as of June 2026. Free cash flow of $-4.67 Million (operating CF $-4.67 Million minus capex $0.00) represents 0% of total liabilities ($15.98 Million). Check BNGO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Bionano Genomics Inc Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Bionano Genomics Inc across 10 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Bionano Genomics Inc.
Annual Financial Flexibility Index for Bionano Genomics Inc (2016–2025)
Year-by-year free cash flow to debt coverage for Bionano Genomics Inc. Explore BNGO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.56x | $-16.34 Million | $-16.34 Million | $29.16 Million | ▲ +66.4% |
| 2024 | -1.67x | $-68.82 Million | $-68.92 Million | $41.30 Million | ▼ -59.6% |
| 2023 | -1.04x | $-123.49 Million | $-125.18 Million | $118.25 Million | ▲ +50.1% |
| 2022 | -2.09x | $-121.51 Million | $-124.82 Million | $58.10 Million | ▼ -18.7% |
| 2021 | -1.76x | $-70.47 Million | $-71.93 Million | $39.98 Million | ▼ -32.8% |
| 2020 | -1.33x | $-33.66 Million | $-38.31 Million | $25.37 Million | ▼ -19.7% |
| 2019 | -1.11x | $-29.47 Million | $-29.53 Million | $26.59 Million | ▲ +17.1% |
| 2018 | -1.34x | $-19.61 Million | $-19.94 Million | $14.67 Million | ▼ -307.8% |
| 2017 | -0.33x | $-19.80 Million | $-20.82 Million | $60.37 Million | ▲ +37.7% |
| 2016 | -0.53x | $-22.15 Million | $-23.50 Million | $42.05 Million | — |